International Ophthalmology

, Volume 36, Issue 1, pp 63–71 | Cite as

A comparative study of different concentrations of topical bevacizumab on the recurrence rate of excised primary pterygium: a short-term follow-up study

  • Qader Motarjemizadeh
  • Naser Samadi Aidenloo
  • Siamak Sepehri
Original Paper


The present study was undertaken to compare the pterygium recurrence rates after treatment with two different concentrations of topical bevacizumab in those who had undergone a primary pterygium excision. The 90 patients who underwent pterygium excision were enrolled in this prospective, placebo-controlled double-blinded interventional case series. The participants were randomly categorized into 3 groups each consisting of 30 subjects. 24 h after surgery, Group II and Group III received a total of 5 and 10 mg/mL dose of topical bevacizumab, respectively; whereas patients in Group I were administered only a placebo starting a day after surgery. Participants were instructed to instill their topical medicines 4 times a day for 1 week. The patients were examined for pterygium recurrence and complications at postoperative 1, 7, and 14 days as well as each month during the following year. Pterygia recurred in 14 patients (46.7 %) in Group I and in 4 patients (13.3 %) in Group II. No recurrence was observed in Group III during the follow-up period. The Kaplan–Meier survival analysis disclosed a significantly better outcome for those who had been treated with 10 mg/mL concentrations of bevacizumab (Mantel–Cox log rank analysis, P < 0.001). The mean recurrence time was not significantly different between Group I and Group II. No ocular or systemic complication developed till the end of follow-up. Thus, 10 mg/mL concentration of topical bevacizumab was more efficacious than 5 mg/mL dose in preventing pterygium recurrence.


Pterygium Recurrence Bevacizumab Bare sclera Iran 



The authors wish to thank all the participants of this study and nursing staff of Imam Khomeini hospital for their valuable cooperation.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Farrah JJ, Lee GA, Greenrod E, Vieira J (2006) Outcomes of autoconjunctival grafting for primary pterygia when performed by consultant compared with trainee ophthalmologists. Clin Exp Ophthalmol 34(9):857–860. doi: 10.1111/j.1442-9071.2006.01341.x CrossRefGoogle Scholar
  2. 2.
    Pinkerton OD, Hokama Y, Shigemura LA (1984) Immunologic basis for the pathogenesis of pterygium. Am J Ophthalmol 98(2):225–228PubMedCrossRefGoogle Scholar
  3. 3.
    Papadia M, Barabino S, Valente C, Rolando M (2008) Anatomical and immunological changes of the cornea in patients with pterygium. Curr Eye Res 33(5):429–434. doi: 10.1080/02713680802130354 PubMedCrossRefGoogle Scholar
  4. 4.
    Chui J, Di Girolamo N, Wakefield D, Coroneo MT (2008) The pathogenesis of pterygium: current concepts and their therapeutic implications. Ocul Surf 6(1):24–43PubMedCrossRefGoogle Scholar
  5. 5.
    Mauro J, Foster CS (2009) Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment. Semin Ophthalmol 24(3):130–134. doi: 10.1080/08820530902801106 PubMedCrossRefGoogle Scholar
  6. 6.
    Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25(2):111–118PubMedCrossRefGoogle Scholar
  7. 7.
    Hosseini H, Nejabat M, Khalili MR (2007) Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses 69(4):925–927. doi: 10.1016/j.mehy.2007.01.047 PubMedCrossRefGoogle Scholar
  8. 8.
    Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13(1):9–22PubMedGoogle Scholar
  9. 9.
    Stevenson W, Cheng SF, Dastjerdi MH, Ferrari G, Dana R (2012) Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf 10(2):67–83. doi: 10.1016/j.jtos.2012.01.005 PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Galor A, Yoo SH, Piccoli FV, Schmitt AJ, Chang V, Perez VL (2010) Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery. Am J Ophthalmol 149(6):926–931. doi: 10.1016/j.ajo.2010.01.015 PubMedCrossRefGoogle Scholar
  11. 11.
    Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333(2):328–335. doi: 10.1016/j.bbrc.2005.05.132 PubMedCrossRefGoogle Scholar
  12. 12.
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342. doi: 10.1056/NEJMoa032691 PubMedCrossRefGoogle Scholar
  13. 13.
    Leippi S, Grehn F, Geerling G (2009) Antiangiogenic therapy for pterygium recurrence. Ophthalmologe 106(5):413–419. doi: 10.1007/s00347-009-1936-y PubMedCrossRefGoogle Scholar
  14. 14.
    Ozgurhan EB, Agca A, Kara N, Yuksel K, Demircan A, Demirok A (2013) Topical application of bevacizumab as an adjunct to recurrent pterygium surgery. Cornea 32(6):835–838. doi: 10.1097/ICO.0b013e3182772d4e PubMedCrossRefGoogle Scholar
  15. 15.
    Wu PC, Kuo HK, Tai MH, Shin SJ (2009) Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea 28(1):103–104. doi: 10.1097/ICO.0b013e3181822615 PubMedCrossRefGoogle Scholar
  16. 16.
    Sanchez-Thorin JC, Rocha G, Yelin JB (1998) Meta-analysis on the recurrence rates after bare sclera resection with and without mitomycin C use and conjunctival autograft placement in surgery for primary pterygium. Br J Ophthalmol 82(6):661–665PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Fallah MR, Khosravi K, Hashemian MN, Beheshtnezhad AH, Rajabi MT, Gohari M (2010) Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res 35(1):17–22. doi: 10.3109/02713680903395273 PubMedCrossRefGoogle Scholar
  18. 18.
    D’Ombrain A (1948) The surgical treatment of pterygium. Br J Ophthalmol 32(2):65–71PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Andreoli CM, Miller JW (2007) Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 18(6):502–508. doi: 10.1097/ICU.0b013e3282f0ca54 PubMedCrossRefGoogle Scholar
  20. 20.
    Manayath GJ, Narendran V, Al-Kharousi N, Wali UK (2009) Bevacizumab therapy for macular edema in central retinal vein occlusion: long-term results. Oman J Ophthalmol 2(2):73–78. doi: 10.4103/0974-620X.53036 PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Jardeleza MS, Miller JW (2009) Review of anti-VEGF therapy in proliferative diabetic retinopathy. Semin Ophthalmol 24(2):87–92. doi: 10.1080/08820530902800330 PubMedCrossRefGoogle Scholar
  22. 22.
    El-Mollayess GM, Noureddine BN, Bashshur ZF (2011) Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment. Semin Ophthalmol 26(3):69–76. doi: 10.3109/08820538.2010.545100 PubMedCrossRefGoogle Scholar
  23. 23.
    Martinez-Carpio PA, Bonafonte-Marquez E, Heredia-Garcia CD, Bonafonte-Royo S (2008) Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review. Arch Soc Esp Oftalmol 83(10):579–588PubMedCrossRefGoogle Scholar
  24. 24.
    Bock F, Konig Y, Kruse F, Baier M, Cursiefen C (2008) Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246(2):281–284. doi: 10.1007/s00417-007-0684-4 PubMedCrossRefGoogle Scholar
  25. 25.
    Chen JJ, Ebmeier SE, Sutherland WM, Ghazi NG (2011) Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye. Eye (Lond) 25(11):1504–1511. doi: 10.1038/eye.2011.225 CrossRefGoogle Scholar
  26. 26.
    Karalezli A, Kucukerdonmez C, Akova YA, Koktekir BE (2014) Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting? Int J Ophthalmol 7(3):512–516. doi: 10.3980/j.issn.2222-3959.2014.03.23 PubMedPubMedCentralGoogle Scholar
  27. 27.
    Sudhalkar A, Sudhalkar A (2012) Outcomes of post-operative topical bevacizumab in primary pterygium surgery: a case series. J Clin Exp Ophthalmol 3(7):243. doi: 10.4172/2155-9570.1000243 CrossRefGoogle Scholar
  28. 28.
    Alhammami H, Farhood Q, Shuber H (2013) Subconjunctival Bevacizumab Injection in Treatment of recurrent Pterygium. J Clin Exp Ophthal 4(267):2. doi: 10.4172/2155-9570.1000267 Google Scholar
  29. 29.
    Nava-Castaneda A, Olvera-Morales O, Ramos-Castellon C, Garnica-Hayashi L, Garfias Y (2014) Randomized, controlled trial of conjunctival autografting combined with subconjunctival bevacizumab for primary pterygium treatment: 1 year follow-up. Clin Exp Ophthalmol 42(3):235–241. doi: 10.1111/ceo.12140 CrossRefGoogle Scholar
  30. 30.
    Felipe AF, Siong RLB, Uy HS (2009) Subconjunctival injection of bevacizumab for treatment of pterygium. Phillip J Ophthalmol 34(1):44–50Google Scholar
  31. 31.
    Khoshniat H, Jahadi Hosseini H, Nejabat M, Fatehi K, Mosallaei M (2009) Local injection of bevacizumab as an alternative method for management of recurrent pterygium. Iran Red Crescent Med J 11(3):306–311Google Scholar
  32. 32.
    Waisbourd M, Levinger E, Varssano D, Moisseiev E, Zayit-Soudri S, Barak A, Loewenstein A, Barequet I (2013) High-dose topical bevacizumab for corneal neovascularization. Pharmacology 92(5–6):310–314. doi: 10.1159/000356407 PubMedCrossRefGoogle Scholar
  33. 33.
    Razeghinejad R, Banifatemi M, Hosseini H (2013) The effect of different doses of subconjunctival bevacizumab on the recurrence rate of excised primary pterygium. Bull Soc Belge Ophtalmol 322:13–20PubMedGoogle Scholar
  34. 34.
    Prabhasawat P, Barton K, Burkett G, Tseng SC (1997) Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology 104(6):974–985PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  • Qader Motarjemizadeh
    • 1
  • Naser Samadi Aidenloo
    • 1
  • Siamak Sepehri
    • 1
  1. 1.Department of OphthalmologyMedical University of UrmiaUrmiaIran

Personalised recommendations